Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Gastroenterology | Oncology | Pathology | Journal

Back to Journal Articles

Aspirin Benefit in Colon Cancer Varies With HLA I Antigen

Last Updated: April 01, 2014.

 

Survival benefit seen for tumors that express HLA class I antigen, but not when HLA antigen is lost

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Aspirin use after colon cancer diagnosis improves survival if tumors express human leukocyte antigen class I antigen, according to a study published online March 31 in JAMA Internal Medicine.

TUESDAY, April 1, 2014 (HealthDay News) -- Aspirin use after colon cancer diagnosis improves survival if tumors express human leukocyte antigen (HLA) class I antigen, according to a study published online March 31 in JAMA Internal Medicine.

Marlies S. Reimers, M.D., from Leiden University Medical Center in the Netherlands, and colleagues modeled survival in a cohort study with tumor blocks from 999 patients with colon cancer, surgically resected between 2002 and 2008. HLA class I antigen and prostaglandin endoperoxide synthase 2 (PTGS2) expression were analyzed, and mutation analysis of PIK3CA was conducted. A prescription database was used to obtain data on aspirin use after diagnosis.

The researchers found that the adjusted rate ratio for the overall survival benefit associated with aspirin use after colon cancer diagnosis was 0.53 (P < 0.001) when tumors expressed HLA class I antigen and 1.03 (P = 0.91) when HLA antigen was lost. A similar benefit of aspirin was seen for tumors with strong and weak PTGS2 expression (rate ratios, 0.68 and 0.59, respectively) and for wild-type PIK3CA tumors (rate ratio, 0.55). There was no correlation noted for mutated PIK3CAtumors (rate ratio, 0.73; P = 0.44).

"Aspirin use after colon cancer diagnosis was associated with improved survival if tumors expressed HLA class I antigen," the authors write. "HLA class I antigen might serve as a predictive biomarker for adjuvant aspirin therapy in colon cancer."

Two authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2014 HealthDay. All rights reserved.


Previous: Hormones, Vaginal Flora Impact Cervicovaginal Lavage Next: Smoke-Free Legislation Has Significant Health Benefits

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.